Drug Profile
Terlipressin intravenous - Orphan Therapeutics
Alternative Names: Lucassin; TERLIVAZLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Orphan Therapeutics LLC
- Developer Mallinckrodt plc; Orphan Therapeutics
- Class Antidiuretics; Antihaemorrhagics; Vasoconstrictors; Vasopressins
- Mechanism of Action Vasopressin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatorenal syndrome
Most Recent Events
- 11 Nov 2023 Pooled efficacy data from a phase-III OT0401, REVERSE and CONFIRM trials in Hepatorenal syndrome presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD -2023)
- 10 Nov 2023 Pooled efficacy data from a phase-III REVERSE and CONFIRM trials in Hepatorenal syndrome presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD -2023)
- 10 Nov 2023 Efficacy data from a phase III CONFIRM trial in Hepatorenal Syndrome presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)